Using a mouse tumor model, Peng and co-workers [94] demonstrated that Gal-3 treatment at high doses abrogates the efficacy of tumor-reactive T cells, induces T-cell apoptosis and promotes tumor immune tolerance. The gene discussed is LGALS3; the disease is neoplasm.